Literature DB >> 1510016

Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy.

L H Cohn1, H Trehan, J J Collins.   

Abstract

The long-term results of patients undergoing myotomy/myectomy of the ventricular septum for obstructive hypertrophic cardiomyopathy are documented in 31 patients (15 women, 16 men, age range 21 to 80 years [mean 55]) with mean New York Heart Association functional class III to IV congestive heart failure, who underwent radical myotomy/myectomy at the Brigham and Women's Hospital from 1972 to 1991. Preoperative gradients by catheterization or echocardiography ranged from 26 to 240 mm Hg (average 96). There were no operative deaths. Two patients developed early postoperative complete heart block requiring a transvenous pacemaker. Clinical follow-up was 1 to 14 years (mean 6.5). All surviving patients were restudied by echocardiography and clinical examination. The mean postoperative functional class was II. Postoperative gradients ranged from 0 to 30 mm Hg (mean 4.5) (p less than 0.001 compared with preoperative values). There were 5 late deaths (low cardiac output in 2, stroke in 2, and acute respiratory failure in 1); 4 of 5 deaths occurred in patients with concomitant coronary artery disease. Survival at 10 years was 86 +/- 9%. There were no reoperations for subaortic obstruction.

Entities:  

Mesh:

Year:  1992        PMID: 1510016     DOI: 10.1016/0002-9149(92)90208-g

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

2.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

Authors:  Mohammed Osman; Babikir Kheiri; Khansa Osman; Mahmoud Barbarawi; Hani Alhamoud; Fahad Alqahtani; Mohamad Alkhouli
Journal:  Clin Cardiol       Date:  2018-11-29       Impact factor: 2.882

3.  Total relief of severe left ventricular outflow obstruction after spontaneous rupture of chordae tendineae in a patient with hypertrophic cardiomyopathy.

Authors:  A Q Araujo; W V Azeredo; E Arteaga; C Mady
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

4.  Aortic valve stenosis with left ventricular outflow tract pressure gradient.

Authors:  T Sasaki; O Okada; T Nakajima; K Komoda; K Kawazoe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-05

Review 5.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007

Review 6.  Percutaneous transluminal septal myocardial ablation.

Authors:  D N Rubin; E M Tuzcu; H M Lever
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

7.  Danon disease for the cardiologist: case report and review of the literature.

Authors:  Ryan S D'souza; Luisa Mestroni; Matthew R G Taylor
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-06-06

8.  Application of 3D printing in the surgical planning of hypertrophic obstructive cardiomyopathy and physician-patient communication: a preliminary study.

Authors:  Hong-Chang Guo; Yang Wang; Jiang Dai; Chang-Wei Ren; Jin-Hua Li; Yong-Qiang Lai
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature.

Authors:  Ahmed M Abdel-Razek; Leonard Y Lee; Robert Tozzi
Journal:  Heart Views       Date:  2011-07

10.  Comparison of surgical results in patients with hypertrophic obstructive cardiomyopathy after classic or modified morrow septal myectomy.

Authors:  Yongqiang Lai; Hongchang Guo; Jinhua Li; Jiang Dai; Changwei Ren; Yang Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.